Cell Counting Market Size, Share & Trends Analysis Report By Product (Instruments, Consumables & Accessories), By Application (Complete Blood Count, Stem Cell Research), By End-use- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Cell Counting market size was estimated at USD 7.55 billion in 2021 and is expected to surpass around USD 15.56 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.25% during the forecast period 2022 to 2030.

Key Takeaways:

• By Product, the U.S. Cell Counting market was valued at USD 2.5 Billion in 2021 and expected to witness growth at a CAGR of 6.9% from 2022 to 2030.
• In the consumables and accessories segment, reagents held the largest revenue share in 2021. The large revenue share is attributed to the repeat purchase of these products for use during spectrophotometry, flow cytometry, and automated cell counting
• The microplates sub-segment is poised to expand at the fastest CAGR during the forecast period. Microplates are usually used for analyzing very low concentration samples. The increased consumption of these plates is attributed to the repeated need to use fresh plates for analyzing a new sample to prevent contamination
• In the instruments segment, automated cell counters are anticipated to grow at an exponential rate during the forecast period. Benefits such as short testing time, reduced error occurrence, and inter-operator variability are expected to further increase the demand for automated counters
• By application, the complete blood count segment held the largest revenue share in 2021. The large revenue share can be attributed to increasing incidence of blood disorders
• In the end-use segment, research and academic institutes accounted for the largest revenue share in 2021 owing to growing number of government initiatives focused on promoting R&D in various toxicology studies
• Pharmaceutical and biotechnology companies are expected to witness exponential growth opportunities owing to the growing adoption of instruments for optimum drug concentration in therapeutics
• North America held the largest revenue share in 2021 owing to an increase in the number of supportive initiatives to fund R&D, which is anticipated to result in higher adoption of automated instruments
• Asia Pacific is anticipated to expand at a lucrative CAGR during the forecast period owing to the large presence of clinical research organizations and biopharmaceutical companies in this region

Growing demand for biologics in the treatment of chronic diseases is one of the factors contributing to the market growth. Biologics development involves the usage of various cell counting products such as flow cytometers and spectrophotometers, which control the cell concentration in biologics, thereby fueling growth prospects for this market. COVID-19 had a substantial impact on the market growth. There was a significant rise in the use of cell counting devices during the pandemic as lymphopenia and eosinopenia were the potential indicators of COVID-19.

Moreover, the study published by BMC in June 2021 concluded that the WBC count of the COVID-19 patient during admission is significantly correlated with the death of patients. A higher level of white blood count should be given further care in the COVID-19 treatment. The growing importance of cell count in patients suffering from Covid-19 has augmented the growth of the market during the pandemic.

Cell counting instruments are progressively being adopted in numerous areas of research such as neuroscience cancer biology and immunology, which exhibit remunerative growth opportunities for the market. The market is also expected to witness exponential growth as blood cell counting is imperative for the assessment of various diseases, and its adoption is anticipated to increase over the forecast period. Moreover, they are extensively used in cancer research to regulate intra-tumor heterogeneity, which is essential for the determination of cancer progression. Cell counting helps in the identification and determination of primary tumors, circulating tumors, and metastatic tumor, which are critical for disease monitoring and therapeutic targeting.

In addition, technological advancements in these devices will offer lucrative opportunities in the study period. For instance, in Dec 2020, Merck launched Scepter 3.0, which is an automated handheld cell counter. Scepter 3.0 can count thousands of cells per measurement with extreme accuracy. In April 2021, CytoSMART Technologies launched automated CytoSMART Exact FL, the company’s first fluorescence cell counter. It is a dual fluorescence device and is used for typical laboratory applications. Similarly, in June 2020, DeNovix launched the first in-the-market imaging cell counter, which eradicates the requirement for slides, thus reducing the environmental footprint of the laboratory.

Government initiatives for promoting cell therapeutics research are widening the growth prospects for the market. Furthermore, funding related to stem cell research has augmented in recent years, which has further accelerated the growth of research. For instance, in September 2021, Stem Cell Research at UCLA and the Eli and Edythe Broad Center of Regenerative Medicine received funding of USD 5 million from the California Institute for Regenerative Medicine.

Report Scope of the Cell Counting Market

Product Insights

Consumables and accessories accounted for the largest revenue share of over 50.4% in 2021. Consumables and accessories used with these devices include reagents, microplates, magnetic beads, and chamber slides. The growth of consumables and accessories is attributed to their high usage volume. Moreover, the launch of novel products propels segment growth. For instance, in December 2020, eNuvio launched a 3D cell culture microplate that is reusable. This novel plate allows scientists to develop embryoid bodies, the compulsory first step to increasing larger organoids or spheroids from stem cells. eNuvio anticipates that scientists will profit from this environmentally friendly device for a long period of time, both economically and scientifically.

Reagents sub-segment held the largest revenue share in 2021. The large revenue share is attributed to the repeated purchase of these products for use during spectrophotometry, flow cytometry, and automated cell counting. Need for frequent recalibrations of these instruments prior to conducting experiments increases their demand.

Application Insights

Complete blood count held the largest revenue share of over 55.1% in 2021. The complete blood count is one of the most common tests used for the evaluation of an individual’s overall health. The test is used to measure several blood components such as RBC, WBC, hemoglobin, hematocrit, and platelets. Increasing incidence of blood disorders such as anemia and leukemia is slated to boost segment growth as complete blood count is commonly used to monitor such conditions.

Stem cell research is anticipated to expand at the fastest CAGR over the forecast period. The exponential growth is a result of the growing need for mass production of human stem cells for clinical and research applications. Stem cells are highly imperative in fields such as regenerative medicine, cancer therapy, and transplantation. Automated devices facilitate the determination of stem cell viability and concentration of nucleated cells in cord blood or human bone marrow accurately. In addition, features such as fluorescence imaging are increasingly being utilized to quantify GFP efficiency for transfecting stem cell applications.

End-use Insights

In 2021, research and academic institutes accounted for the largest revenue share of over 35.2%. The dominant share can be attributed to the extensive adoption of cytometers in cell biology research studies. Cytometers find applications in measuring parameters such as physical properties, type, and lineage, which are used by researchers to study the progression of viruses, pathogens, and other bacteria. Strategic activities by key market players further drive the segment. For instance, in March 2021, Alliance Global installed an Automated Cell Counter system at the United Arab Emirates University in Al Ain.

Pharmaceutical and biotechnology companies are anticipated to grow exponentially during the forecast period. Cell counting is an important aspect of checking the potency of any biological product. These devices are used to determine the number of cells in a particular culture solution, which is then added to the bioreactors/fermenters to achieve the desired product. Increasing demand for biologics produced through bioprocessing in these bioreactors/fermenters is anticipated to boost device demand over the forecast years.

Regional Insights

In 2021, North America accounted for the largest revenue share of over 35.2% owing to the increasing focus on biomedical and cancer research. The rise in the prevalence of chronic diseases, such as cardiovascular and blood diseases, is one of the major factors anticipated to fuel the adoption of these devices. As per the American National Red Cross, in the U.S., sickle cell disease affects 90,000 to 100,000 individuals.

Asia Pacific is expected to grow at an exponential rate throughout the forecast period. This exponential CAGR can be attributed to the local presence of certain clinical research and biopharmaceutical companies across this region. In addition, the growing geriatric population, which is highly susceptible to chronic diseases, is predominantly driving the market in the region. This has resulted in an increase in the adoption of these devices at an unprecedented rate owing to an increase in the number of clinical tests conducted annually for geriatric patients.

Some of the prominent players in the Cell Counting Market include:

• ThermoFisher Scientific, Inc.
• Merck KGaA
• Agilent Technologies
• PerkinElmer, Inc.
• BD
• Danaher
• Bio-Rad Laboratories, Inc.
• BioTek Instruments, Inc.
• GE Healthcare
• DeNovix Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cell Counting market

• Product
• Instruments

• Spectrophotometers
• Flow Cytometers
• Hemocytometers
• Automated Cell Counters
• Microscopes
• Others
• Consumables & Accessories
• Reagents
• Microplates
• Others
• Application
• Complete Blood Count
• Automated Cell Counters
• Manual Cell Counters
• Stem Cell Research
• Cell Based Therapeutics
• Bioprocessing
• Toxicology
• Others
• End-use
• Hospitals & Diagnostic Laboratories
• Research & Academic Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Points Covered in Cell Counting Market Study:

• Growth of Cell Counting in 2022
• Market Estimates and Forecasts (2017-2030)
•  Brand Share and Market Share Analysis
•  Key Drivers and Restraints Shaping Market Growth
•  Segment-wise, Country-wise, and Region-wise Analysis
•  Competition Mapping and Benchmarking
•  Recommendation on Key Winning Strategies
•  COVID-19 Impact on Demand for Cell Counting and How to Navigate
•  Key Product Innovations and Regulatory Climate
•  Cell Counting Consumption Analysis
•  Cell Counting Production Analysis
•  Cell Counting and Management